KalVista Pharmaceuticals, Inc.KALVNASDAQ
Loading
Operating Expenses Over TimeStrong
Percentile Rank100
3Y CAGR+21.8%
5Y CAGR+64.5%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+21.8%/yr
vs +24.6%/yr prior
5Y CAGR
+64.5%/yr
Recent deceleration
Acceleration
-2.8pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
12x
Strong expansion
Streak
2 yr
Consecutive growthStrong
| Period | Value | YoY Change |
|---|---|---|
| TTM | $200.43M | +6.6% |
| 2025 | $188.00M | +246.4% |
| 2024 | $54.28M | -51.0% |
| 2023 | $110.87M | +14.8% |
| 2022 | $96.61M | +480.7% |
| 2021 | $16.64M | +27.7% |
| 2020 | $13.03M | -71.6% |
| 2019 | $45.95M | +69.6% |
| 2018 | $27.10M | +13.7% |
| 2017 | $23.84M | - |